DNAG DNAPrint Genomics Inc (CE)

Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) ("Nanobac" or "the Company�) is pleased to announce a jointly signed letter of intent for the acquisition of DNAPrint Genomics, Inc. (OTCBB:DNAG) (�DNAPrint� or DNAP). With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development. Nanobac adds advanced drug and diagnostics development programs, key patents and patent applications, and a proprietary product modeling platform to its existing initiatives, and expands its focus into multiple disease sites for both Diagnostics and Therapeutics. The combined company would have annualized revenue of approximately $5,000,000, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University. DNAPrint Genomics has developed, patented and published various technologies for an improved, 21st century model of clinical product development - aimed at maximizing effectiveness, minimizing unintended effects, reducing costs and shifting the risk to reward ratio during clinical product development. These tools include extensively validated and published genome assays for individualized assessments of genetic ancestry on multiple levels (consumer products segment), tools for the inference of physical characteristics for the forensics market, tools for the inference of patient proclivities to respond to treatments (pharmacogenomics) and meta-analytical systems for computationally modeling the biology of clinical products for a more intelligent approach to drug and diagnostic development. DNAG's primary objective has been, and Nanobac's primary objective will be, to develop progressive theranostics drugs, which combine extensively modeled drugs with genomics-derived intelligence to create more economical and powerful drug/test combination products with superior performance parameters. DNAG's flagship product, PT-401, is expected to result in more effective treatment of anemia, and its Protectin(TM) (CD-59) diagnostic test is expected to allow patients and their physicians to more effectively manage the risks and treatment decisions for diabetes. DNAG supports its clinical programs, in part, through the sale of consumer genetics tests genotyping services on a contractual basis. �Dr Hector Gomez has been on the Company�s advisory board giving Nanobac the benefit of evaluating DNAG�s technologies and portfolio of products,� said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals. �Combining our diagnostic portfolios, specifically DNAP�s Protectin� and Nanobac�s NB2 has the potential to play a significant role in the early diagnosis of vascular disease and could potentially help in identifying early signs and progression of cardiovascular disease,� Dr. Maniscalco concluded. "The Protectin(TM) test will be used to identify diabetics at risk of developing vascular complications," said Dr. Gomez, Chairman of DNAP. "Protectin(TM) is anticipated to become a new tool in the complex understanding of Diabetes and could potentially replace HbA1c, the current test used to evaluate glucose control. Combined with Nanobac's diagnostic portfolio, Protectin(TM) is expected to dramatically increase the physician's ability to diagnose patients at significant cardiovascular risk," concluded Dr. Gomez. According to Global Industry Analysts, the international global diabetes diagnostic supplies market is expected to grow to US$15.4 billion by 2010. This indicates significant potential for the Protectin� test. Additionally, cardiovascular diagnostics will see a high rate of growth also, increasing from $11.9 billion in 2007 to $21.4 billion by the end of 2012. The cardiovascular diagnostics market represents one of the largest sectors within the diagnostics industry, chiefly due to the high prevalence rate of and high mortality rate from cardiovascular disease. DNAG�s flagship PT-401 therapeutic, in pre-clinical stages, is a genetically engineered erythropoietin dimmer (double form), which elicits a heartier, longer lasting increase in hematocrit for anemic patients. The singlet form of erythropoietin was introduced by Amgen Corporation in 1989, and enjoys a $2B in annual sales. A successfully approved PT-401 alternative is expected to allow physicians to treat patients with less drug and at less frequent intervals, at significant savings, while at the same time, increasing the consistency of therapeutic response. Nanobac Pharmaceuticals is the leader in research and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac Pharmaceuticals markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases. Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com. Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.